Press-release for stocks related to therapeutics

Prices are updated after-hours

tags : Therapeutics

save search

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BIOR | $0.6156 2.69% 2.62% 100K

Health Care and Social Assistan...

| -16.09% | O: 1.34% H: 0.0% C: -4.21%
bt-600 positive trial therapeutics results platform

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.17 -5.31% -5.61% 520K

| 241.25% | O: 26.87% H: 276.85% C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
ACHL | $0.7827 -2.16% -2.21% 200K

Manufacturing

| -31.44% | O: -16.22% H: 0.99% C: -7.89%
business therapeutics financial results

Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
APLT A | $4.4 -7.17% -7.73% 2.9M

Health Technology

| -19.15% | O: -2.35% H: 7.72% C: -4.82%
therapeutics results study diabetic

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
ADCT | $4.72 -0.84% 0.0% 320K

Health Technology

| 7.94% | O: 0.68% H: 11.71% C: 6.08%
zynlonta trial therapeutics

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
ACHL | $0.7827 -2.16% -2.21% 200K

Manufacturing

| -31.44% | O: -16.22% H: 0.99% C: -7.89%
first melanoma update therapeutics advanced

Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight
Published: 2024-04-03 (Crawled : 22:00) - prnewswire.com
PLRX | $12.51 2.63% 2.56% 310K

Health Technology

| -15.52% | O: 1.87% H: 3.4% C: -1.02%
fibrosis therapeutics growth market

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Published: 2024-04-03 (Crawled : 21:00) - globenewswire.com
TVTX | $5.73 -1.21% -1.22% 950K

Health Technology

| -14.18% | O: 1.58% H: 1.13% C: -1.97%
filspari nephropathy congress association world therapeutics

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2024-04-03 (Crawled : 20:00) - globenewswire.com
BIOR | $0.6156 2.69% 2.62% 100K

Health Care and Social Assistan...

| -16.09% | O: 1.34% H: 0.0% C: -4.21%
nasdaq million direct offering therapeutics

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-03 (Crawled : 19:00) - biospace.com/
FATE | $4.795 -4.86% -5.11% 2.7M

Health Technology

| -20.88% | O: -0.29% H: 7.52% C: 3.39%
conference therapeutics

Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
Published: 2024-04-03 (Crawled : 14:30) - biospace.com/
LGND | $72.59 0.1% 0.1% 140K

Health Technology

| 7.73% | O: -0.83% H: 3.14% C: 2.93%
pharmaceuticals commercialization therapeutics

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
Published: 2024-04-03 (Crawled : 13:00) - globenewswire.com
LSTA | $2.85 -5.82% 2K

Manufacturing

| -9.74% | O: 0.65% H: 0.0% C: -1.94%
therapeutics

TransCode Therapeutics Reports 2023 Results; Provides Business Update
Published: 2024-04-03 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.49 -2.39% -2.45% 110K

Professional, Scientific, and T...

| -26.7% | O: -1.04% H: 1.48% C: -3.7%
business update therapeutics

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
ALGS | $0.735 -7.33% -7.9% 140K

Health Technology

| -19.22% | O: 2.25% H: 4.0% C: 1.0%
alg-0550 first therapeutics study

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
CRSP M | $55.04 -1.99% -2.03% 1.8M

Health Technology

| -10.87% | O: -0.46% H: 1.12% C: -0.2%
conference crispr therapeutics

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
CTMX | $1.67 -3.47% -3.59% 510K

Health Technology

| -13.08% | O: -0.47% H: 2.35% C: 0.94%
probody candidate t-cell collaboration therapeutics

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
IKT | $2.1 0.19% 52K

Health Technology

| -2.33% | O: -0.93% H: 7.04% C: 0.94%
fda meeting hypertension therapeutics

Nurix Therapeutics to Participate in Upcoming Investor Conferences - April 03, 2024
Published: 2024-04-03 (Crawled : 12:00) - biospace.com/
NRIX | $13.6 -5.82% -6.18% 1M

Health Technology

| -2.83% | O: -1.28% H: 0.68% C: -0.55%
therapeutics

Nurix Therapeutics to Participate in Upcoming Investor Conferences
Published: 2024-04-03 (Crawled : 11:00) - globenewswire.com
NRIX | $13.6 -5.82% -6.18% 1M

Health Technology

| -2.83% | O: -1.28% H: 0.68% C: -0.55%
therapeutics